BACKGROUND: The magnitude of benefit of trastuzumab for the treatment of advanced HER2-positive breast cancer varies widely. In this retrospective study, we investigated the clinicopathological features associated with prolonged first-line trastuzumab-based treatment duration. PATIENTS AND METHODS: A total of 164 patients diagnosed with advanced HER2-positive breast cancer and treated with first-line trastuzumab-based therapy from 1999 to 2009 were identified. Duration of treatment was classified according to tertiles. Different logistic regression models including age, disease-free interval, number of metastatic sites, visceral disease, hormone receptor, and adjuvant trastuzumab were fitted to investigate associations with benefit of prolonged trastuzumab-based therapies. The predictive value of each model was assessed using C-statistics. RESULTS: At a median follow-up of 5.8 years (range, 0.7-22.1 years), patients in the short-, intermediate-, and long-term treatment duration groups were given first-line trastuzumab-based therapy for < 7.2 months, 7.2 to 14 months, and > 14 months, respectively. In the multivariate analysis, patients with long-term clinical benefit had a higher likelihood of having hormone receptor-positive tumors (odds ratio [OR]positive vs. negative = 2.39 [95% confidence interval (CI), 1.08-5.31]; P = .032); and a lower likelihood of having received adjuvant trastuzumab (ORadjuvant trastuzumab vs. no adjuvant trastuzumab = 0.30 [95% CI, 0.10-0.96]; P = .043]. C-statistics varied between 0.634 and 0.699. CONCLUSION: Long-term benefit of trastuzumab-based therapy is associated with hormone receptor positivity and the absence of previous adjuvant trastuzumab. Nevertheless, clinicopathological features had a low predictive value for prolonged treatment duration. The validation of the current findings and the identification of molecular features associated the magnitude of trastuzumab benefit should be encouraged.
BACKGROUND: The magnitude of benefit of trastuzumab for the treatment of advanced HER2-positive breast cancer varies widely. In this retrospective study, we investigated the clinicopathological features associated with prolonged first-line trastuzumab-based treatment duration. PATIENTS AND METHODS: A total of 164 patients diagnosed with advanced HER2-positive breast cancer and treated with first-line trastuzumab-based therapy from 1999 to 2009 were identified. Duration of treatment was classified according to tertiles. Different logistic regression models including age, disease-free interval, number of metastatic sites, visceral disease, hormone receptor, and adjuvant trastuzumab were fitted to investigate associations with benefit of prolonged trastuzumab-based therapies. The predictive value of each model was assessed using C-statistics. RESULTS: At a median follow-up of 5.8 years (range, 0.7-22.1 years), patients in the short-, intermediate-, and long-term treatment duration groups were given first-line trastuzumab-based therapy for < 7.2 months, 7.2 to 14 months, and > 14 months, respectively. In the multivariate analysis, patients with long-term clinical benefit had a higher likelihood of having hormone receptor-positive tumors (odds ratio [OR]positive vs. negative = 2.39 [95% confidence interval (CI), 1.08-5.31]; P = .032); and a lower likelihood of having received adjuvant trastuzumab (ORadjuvanttrastuzumab vs. no adjuvant trastuzumab = 0.30 [95% CI, 0.10-0.96]; P = .043]. C-statistics varied between 0.634 and 0.699. CONCLUSION: Long-term benefit of trastuzumab-based therapy is associated with hormone receptor positivity and the absence of previous adjuvant trastuzumab. Nevertheless, clinicopathological features had a low predictive value for prolonged treatment duration. The validation of the current findings and the identification of molecular features associated the magnitude of trastuzumab benefit should be encouraged.
Authors: Michel Marty; Francesco Cognetti; Dominique Maraninchi; Ray Snyder; Louis Mauriac; Michèle Tubiana-Hulin; Stephen Chan; David Grimes; Antonio Antón; Ana Lluch; John Kennedy; Kenneth O'Byrne; PierFranco Conte; Michael Green; Carol Ward; Karen Mayne; Jean-Marc Extra Journal: J Clin Oncol Date: 2005-05-23 Impact factor: 44.544
Authors: Harold J Burstein; Lyndsay N Harris; P Kelly Marcom; Rosemary Lambert-Falls; Kathleen Havlin; Beth Overmoyer; Robert J Friedlander; Janet Gargiulo; Rochelle Strenger; Charles L Vogel; Paula D Ryan; Mathew J Ellis; Raquel A Nunes; Craig A Bunnell; Susana M Campos; Michele Hallor; Rebecca Gelman; Eric P Winer Journal: J Clin Oncol Date: 2003-08-01 Impact factor: 44.544
Authors: Thomas Yau; Charles Swanton; Sue Chua; Ashley Sue; Geraldine Walsh; A Rostom; Stephen R Johnston; Mary E R O'Brien; Ian E Smith Journal: Acta Oncol Date: 2006 Impact factor: 4.089
Authors: Juan Lucas Bayo-Calero; José I Mayordomo; Pedro Sánchez-Rovira; Ramón Pérez-Carrión; José J Illaramendi; José M García-Bueno; Encarnación González-Flores; Carmen Crespo; Manuel Ramos-Vázquez; Andrés García-Palomo; Manuel Ruiz-Borrego; Juan de la Haba; Amalia Gómez-Bernal; Alfonso Yubero-Esteban Journal: Clin Breast Cancer Date: 2008-06 Impact factor: 3.225
Authors: Zhiyuan Hu; Cheng Fan; Daniel S Oh; J S Marron; Xiaping He; Bahjat F Qaqish; Chad Livasy; Lisa A Carey; Evangeline Reynolds; Lynn Dressler; Andrew Nobel; Joel Parker; Matthew G Ewend; Lynda R Sawyer; Junyuan Wu; Yudong Liu; Rita Nanda; Maria Tretiakova; Alejandra Ruiz Orrico; Donna Dreher; Juan P Palazzo; Laurent Perreard; Edward Nelson; Mary Mone; Heidi Hansen; Michael Mullins; John F Quackenbush; Matthew J Ellis; Olufunmilayo I Olopade; Philip S Bernard; Charles M Perou Journal: BMC Genomics Date: 2006-04-27 Impact factor: 3.969
Authors: Laurent Perreard; Cheng Fan; John F Quackenbush; Michael Mullins; Nicholas P Gauthier; Edward Nelson; Mary Mone; Heidi Hansen; Saundra S Buys; Karen Rasmussen; Alejandra Ruiz Orrico; Donna Dreher; Rhonda Walters; Joel Parker; Zhiyuan Hu; Xiaping He; Juan P Palazzo; Olufunmilayo I Olopade; Aniko Szabo; Charles M Perou; Philip S Bernard Journal: Breast Cancer Res Date: 2006-04-20 Impact factor: 6.466
Authors: Jason I Herschkowitz; Karl Simin; Victor J Weigman; Igor Mikaelian; Jerry Usary; Zhiyuan Hu; Karen E Rasmussen; Laundette P Jones; Shahin Assefnia; Subhashini Chandrasekharan; Michael G Backlund; Yuzhi Yin; Andrey I Khramtsov; Roy Bastein; John Quackenbush; Robert I Glazer; Powel H Brown; Jeffrey E Green; Levy Kopelovich; Priscilla A Furth; Juan P Palazzo; Olufunmilayo I Olopade; Philip S Bernard; Gary A Churchill; Terry Van Dyke; Charles M Perou Journal: Genome Biol Date: 2007 Impact factor: 13.583
Authors: Hánah N Rier; Mark-David Levin; Joost van Rosmalen; Monique M E M Bos; Jan C Drooger; Paul de Jong; Johanneke E A Portielje; Elisabeth M P Elsten; Albert-Jan Ten Tije; Stefan Sleijfer; Agnes Jager Journal: Oncologist Date: 2017-05-22
Authors: Otto Metzger-Filho; Evandro de Azambuja; Marion Procter; Magalie Krieguer; Ian Smith; Jose Baselga; David Cameron; Michael Untch; Christian Jackisch; Richard Bell; Luca Gianni; Aron Goldhirsch; Martine Piccart; Richard D Gelber Journal: Breast Cancer Res Treat Date: 2015-12-26 Impact factor: 4.872
Authors: Benjamin Daniels; Sarah J Lord; Belinda E Kiely; Nehmat Houssami; Philip Haywood; Christine Y Lu; Robyn L Ward; Sallie-Anne Pearson Journal: BMJ Open Date: 2017-01-24 Impact factor: 2.692